Bharathi DR

Antibiotic Prophylaxis should be appropriate to reduce the risk of postoperative surgical infections. Surgical Site Infections (SSIs) are responsible for Increased Mortality and Morbidity rate during surgical operations which lead to major complications. The inappropriate and overuse of antibiotics effects the cost and efficacy of drugs which leads to the resistant bacteria. To assess the pattern of antibiotic usage in surgical in-patients and for Postoperative wound infections. The present study is a prospective observational study done for a period of six months in Basaweshwara Medical College and Research Centre, Chitradurga in surgical ward. A Total of 162 patients were enrolled into the study. Among them, Surgical Site Infection (SSIs) was found in 37 (22.8%) patients and patients without SSIs are 125 (77.2%). The patients with age group 25-60 years were 104 (64.2%) in which SSIs are more (23).According to the study male patients underwent more surgeries (107 (66%)) in which 21 (56.8%) are with SSIs. Infection rate were more in males when compare to females in the study. A total of 265 antibiotics were used among 162 patients in which third generation cephalosporins are more preferred. The study concludes that there is a proper need to control the use of antibiotics appropriately. The inappropriate use leads to economic burden and resistance. SSIs may decrease the quality of life of the patients. Hence minimization of SSI is also very important in the developing countries by maintaining infection control plans by suitable organizations which makes an impact on the infections

The goal of the present investigation was to formulate and evaluate chitosan and Eudragit Nanoparticles of Stavudine for antiviral therapy. Nanoparticles of Stavudine were prepared using chitosan, Eudragit S 100, liquid paraffin and Tween-20 using Emulsion droplet coalescence method. The concentration of the polymers Chitosan and Eudragit S 100 were selected based on the results on preliminary screening. The nanoparticles prepared were evaluated for morphology, loading efficiency and in-vitro release. The particle shape and morphology of the prepared Stavudine nanoparticles were determined by SEM analysis. The amount of Stavudine entrapment in the nanoparticles was calculated by the difference between the total amount of drug added to the nanoparticle and the amount of non-entrapped drug remaining in the aqueous supernatant. A Franz diffusion cell was used to monitor Stavudine release from the nanoparticles. The formulations CF1, CF2, EF2 and EF3 showed good drug release from the polymer. The percentage cumulative drug release after 12 hours was 75.54, 75.89, 78.86 and 76.42% respectively. However about 15% initial burst release was found at 1 hour in all formulations. EF2 released 78.86% of Stavudine 12 hours with a burst drug release nearly 14.86% of drug within the initial 1 hour. Formulations 4 out of 8showed good drug release from the polymer, the percentage cumulative drug release after 12 hours were in the range of 72-78 %. Among the four formulations EF 2 (1% Chitosan & 1.5 % EudragitS 100) showed maximum drug release in 12 hours diffusion study and good entrapment efficiency. In-vitro antiviral study revealed thatthe formulated nanoparticles were found to have good viral activity on viral cells in sustained manner.

This present review is progress in selected nanotechnology topics and some possible applications. This attempt mainly focused on Different Classes of Nanoparticles (Ceramic nanoparticles, Metallic particles, Carbon nanomaterials, Quantum dots) and Applications of Nanotechnology in Pharmaceuticals (Diagnosis, Pharmacology and Therapy, Molecular Diagnosis) and Nanoparticle Drug Delivery Systems and Toxicity of Nanoparticles. Nanoparticles mainly use aims to minimize drug degradation upon administration, prevent undesirable side effects, and increase drug bioavailability and the fraction of the drug accumulated in the pathological area.

Lornoxicam is comparatively a new non-steroidal anti-inflammatory drug, which is selective cyclooxygenase-1 and 2 (COX 1 and 2) inhibitors. Lornoxicam is a non steroidal anti-inflammatory drug that exhibits its anti inflammatory, analgesic and anti pyretic activities in animal models and it is presently available in the market only as tablet dosage form. It is preferred in the treatment of adults with osteoarthritis, acute pain rheumatoid arthritis, postoperative dental pain and primary dysmenorrhoea. The present study was undertaken with an intention to develop a stable and effective parenteral formulation, containing the drug Lornoxicam. Lornoxicam is a light sensitive and insoluble water soluble drug but unstable at higher temperature in water. So the effects of various co solvents in the solubility of  Lornoxicam have been evaluated. Lornoxicam was tried with co solvents such as PEG-400, β-cyclodextrin and Sodium Lauryl sulphate. The drug was made into injection formulation for administered as a SVP. Various batches of Lornoxicam injection formulation were prepared in order to assess the influence of heat, light, atmospheric oxygen and antioxidant on the stability of the drug and the formulations were also subjected to accelerated stability test. Out of all trials, formulation containing Sodium Lauryl sulphate was found to be more soluble, stable and passed all tests satisfactorily.